Everyone’s eyes are set on the vaccine amidst the havoc of the corona virus. Meanwhile, the good news is that Serum Institute, which is testing the Oxford and AstraZeneca vaccine in India, has overcome the major challenge of the third phase clinical trial of the Kovid-19 vaccine. According to the news agency ANI, the Serum Institute of India and ICMR have announced that the Phase III enrollment of clinical trials for COVISHIELD has been completed in India.
According to the agency, ICMR and Serum Institute are also working together for clinical development of Kovovax (COVOVAX, Novavax). COVOVAX has been developed by Novavax in the US and Serum Institute is working to expand it further.
Serum Institute of India & ICMR, announces completion of enrolment of phase 3 clinical trials for COVISHIELD in India. ICMR & SII have further collaborated for clinical development of COVOVAX (Novavax) developed by Novavax, USA & upscaled by SII: Serum Institute of India# COVID19 pic.twitter.com/1iUlbX4ouh
– ANI (@ANI) November 12, 2020
Earlier, Adar Poonawalla, CEO of Pune-based country’s largest drug maker Serum Institute of India, said that the corona vaccine may be available in the country by January 2021. Adar Poonawalla had said that the success of the tests in India and the United Kingdom and if the regulatory bodies are approved in time, along with that if it proves to be resistant and effective, we can expect that in India next January Till the vaccine will be available. “
Let us know that the Serum Institute is working with the British-Swedish pharmaceutical company Astragenica to manufacture the Kovid-19 vaccine. Kovishield has been prepared by Oxford University and the second and third phase trials are currently underway in the country. It is being prepared by Serum Institute for low and middle income countries.